Meng Hao 1 , 2 , Guanying Zhang 2 , Shengnan Zhang 3 , Zhengshan Chen 4 , Xiangyang Chi 2 , Yunzhu Dong 2 , Pengfei Fan 2 , Yujiao Liu 2 , Yi Chen 2 , Xiaohong Song 2 , Shuling Liu 2 , Changming Yu 2 , * , Jianmin Li 2 , * , Xianzhu Xia 1 , 5 , *
27 February 2020
The Rift Valley fever virus (RVFV) is an arthropod-borne virus that can not only cause severe disease in domestic animals but also in humans. However, the licensed vaccines or available therapeutics for humans do not exist. Here, we report two Gn-specific neutralizing antibodies (NAbs), isolated from a rhesus monkey immunized with recombinant human adenoviruses type 4 expressing Rift Valley fever virus Gn and Gc protein (rHAdV4-GnGcopt). The two NAbs were both able to protect host cells from RVFV infection. The interactions between NAbs and Gn were then characterized to demonstrate that these two NAbs might preclude RVFV glycoprotein rearrangement, hindering the exposure of fusion loops in Gc to endosomal membranes after the virus invades the host cell. The target region for the two NAbs is located in the Gn domain III, implying that Gn is a desired target for developing vaccines and neutralizing antibodies against RVFV.